US 12,458,345 B2
Method for implementing a staple system
Jason M. Rector, Maineville, OH (US); Michael J. Vendely, Lebanon, OH (US); Frederick E. Shelton, IV, Hillsboro, OH (US); Jason L. Harris, Lebanon, OH (US); Ryan W. McGhee, Cincinnati, OH (US); Benjamin A. Roll, Cincinnati, OH (US); Shashi S. Pathak, Mason, OH (US); Shannon L. Jones, Cincinnati, OH (US); and Stefan Beck, Niederdorf (CH)
Assigned to Cilag GmbH International, Zug (CH)
Filed by Cilag GmbH International, Zug (CH)
Filed on Apr. 12, 2022, as Appl. No. 17/718,823.
Claims priority of provisional application 63/186,519, filed on May 10, 2021.
Prior Publication US 2022/0354487 A1, Nov. 10, 2022
Int. Cl. A61B 17/72 (2006.01); A61B 17/064 (2006.01); A61B 17/072 (2006.01); A61B 17/10 (2006.01); A61B 50/30 (2016.01); A61B 90/98 (2016.01); A61L 31/02 (2006.01); A61L 31/04 (2006.01); A61L 31/10 (2006.01); A61L 31/14 (2006.01); A61L 31/16 (2006.01); B23P 15/00 (2006.01); A61B 17/00 (2006.01); A61B 17/068 (2006.01); A61B 90/00 (2016.01)
CPC A61B 17/0644 (2013.01) [A61B 17/064 (2013.01); A61B 17/072 (2013.01); A61B 17/07207 (2013.01); A61B 17/105 (2013.01); A61B 50/3001 (2016.02); A61B 90/98 (2016.02); A61L 31/022 (2013.01); A61L 31/028 (2013.01); A61L 31/042 (2013.01); A61L 31/048 (2013.01); A61L 31/10 (2013.01); A61L 31/148 (2013.01); A61L 31/16 (2013.01); A61B 2017/00004 (2013.01); A61B 2017/00022 (2013.01); A61B 2017/00084 (2013.01); A61B 2017/00119 (2013.01); A61B 2017/00845 (2013.01); A61B 17/0686 (2013.01); A61B 2017/0688 (2013.01); A61B 2017/07228 (2013.01); A61B 2017/07235 (2013.01); A61B 2017/07257 (2013.01); A61B 2017/07264 (2013.01); A61B 2017/07271 (2013.01); A61B 2017/07278 (2013.01); A61B 2017/07285 (2013.01); A61B 2050/3004 (2016.02); A61B 2090/0807 (2016.02)] 19 Claims
OG exemplary drawing
 
1. A method of preparing a staple cartridge, the method comprising:
forming first staples with a first alloy, wherein the first staples comprise a material configured to deliver radiotherapy into a tissue environment within a patient, the material comprising a doped alloy comprising an alpha particle emitter;
forming second staples with a second alloy that is different than the first alloy;
positioning the first staples into staple cavities of a first row of staple cavities of the staple cartridge, wherein the first row of staple cavities is a first distance from an elongate slot of the staple cartridge; and
positioning the second staples into staple cavities of a second row of staple cavities, wherein the second row of staple cavities is a second distance from the elongate slot of the staple cartridge, wherein the second distance is greater than the first distance;
wherein the first staples are configured to degrade at a first rate in the tissue environment within the patient, and wherein the second staples are configured to degrade at a second rate in the tissue environment that is different than the first rate.